Cover ImageSALE
市場調查報告書

腦監測設備的全球市場:2017年∼2021年

Global Brain Monitoring Devices Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 344845
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
腦監測設備的全球市場:2017年∼2021年 Global Brain Monitoring Devices Market 2017-2021
出版日期: 2017年06月28日 內容資訊: 英文 95 Pages
簡介

全球腦監測設備市場,預計從2017年到2021年之間,以8.72%的年複合成長率 (CAGR) 擴大。

本報告提供全球腦監測設備市場上現狀和未來預測相關調查分析,市場概要,產品,用途,種類,及各地區的市場分析,市場上各種影響因素分析,主要供應商等相關彙整。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 市場調查手法

第4章 簡介

  • 主要市場洞察

第5章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 市場區隔:各產品

  • EEG設備
  • MEG設備
  • TCD設備
  • ICP設備
  • 腦血氧計

第7章 各檢驗方法的市場區隔

  • 市場概要
  • 非侵入性檢驗
  • 侵入性檢驗

第8章 各終端用戶的市場區隔

  • 市場概要
  • 醫院
  • 外科門診診療所
  • 家庭
  • 研究機關
  • 腦神經中心
  • 救護車

第9章 地區區分

  • 概要
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區

第10章 決策架構

第11章 市場成長因素與課題

  • 市場成長因素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

第14章 主要供應商分析

  • Compumedics
  • GE Healthcare
  • Medtronic
  • Natus Medical
  • 日本光電

第15章 附錄

  • 簡稱清單

第16章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR13562

About Brain Monitoring Devices

Brain monitoring is the process of tracking multiple activities associated with the functioning of the brain. These activities are measured with the help of brain monitoring devices that measure either electrical activity, blood flow & magnetic activity, pressure measurement around the brain, cerebral oxygen, or saturation. These devices are used for monitoring the conditions of individuals with Alzheimer's disease, epilepsy, multiple sclerosis (MS), and traumatic brain injury (TBI).

Technavio's analysts forecast the global brain monitoring devices market to grow at a CAGR of 8.72% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global brain monitoring devices market for 2017-2021. To calculate the market size, the report considers revenue generated by the sales of different brain monitoring devices.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Brain Monitoring Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Compumedics
  • GE Healthcare
  • Medtronic
  • Natus Medical
  • NIHON KOHDEN

Other Prominent Vendors

  • Advanced Brain Monitoring
  • CAS Medical Systems
  • Clinical Science System
  • Elekta
  • EMS Biomedical
  • Integra LifeSciences
  • Masimo
  • Nonin Medical
  • Ornim
  • Tristan Technologies

Market driver

  • Increasing number of neurological patients
  • For a full, detailed list, view our report

Market challenge

  • Under-penetration of market
  • For a full, detailed list, view our report

Market trend

  • Application of health informatics and monitoring solutions
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline analysis

PART 07: Market segmentation based on drug class

  • Management of OAB
  • Anticholinergic agents
  • Beta-3-adrenoreceptor agonists
  • Others

PART 08: Drug profile of key OAB therapeutics

  • TOVIAZ
  • VESIcare
  • Betanis/Myrbetriq/BETMIGA

PART 09: Geographical segmentation

  • OAB therapeutics market in Americas
  • OAB therapeutics market in EMEA
  • OAB therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Advancing biomedical science
  • Advent of novel drug delivery systems
  • Gene therapy in OAB

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Pfizer
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Prevalence rate of OAB in women aged under 25 years versus women aged over 65 years
  • Exhibit 02: OAB pathophysiology
  • Exhibit 03: Global OAB therapeutics market snapshot
  • Exhibit 04: Global OAB therapeutics market 2016-2021 ($ millions)
  • Exhibit 05: Opportunity analysis of global OAB therapeutics market
  • Exhibit 06: Five forces analysis
  • Exhibit 07: Pipeline molecules at various developmental stage
  • Exhibit 08: Pipeline molecules arranged as per drug class
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Purpose of key clinical trials
  • Exhibit 11: Segmentation of global OAB therapeutics market by drug class 2016
  • Exhibit 12: Global OAB therapeutics market share by drug class, 2016
  • Exhibit 13: Global OAB therapeutics market segmentation by drug class 2016
  • Exhibit 14: Global OAB anticholinergic therapeutics market 2016-2021 ($ millions)
  • Exhibit 15: Types of ACh receptors
  • Exhibit 16: Mechanism of action of MRA
  • Exhibit 17: Global OAB beta-3 adrenoreceptor agonists market 2016-2021 ($ millions)
  • Exhibit 18: Mechanism of action of mirabegron
  • Exhibit 19: Global OAB therapeutics market for others 2016-2021 ($ millions)
  • Exhibit 20: TOVIAZ year-over-year (YoY) revenue 2010-2016 ($ millions)
  • Exhibit 21: VESIcare revenue in different regions in 2015-2016 ($ millions)
  • Exhibit 22: Betanis/Myrbetriq/BETMIGA revenue in different regions 2015-2016 ($ millions)
  • Exhibit 23: Betanis/Myrbetriq/BETMIGA patents
  • Exhibit 24: History of drug approvals in OAB
  • Exhibit 25: Segmentation of global OAB therapeutics market by geography 2016 and 2021
  • Exhibit 26: Global OAB therapeutics market revenue by geography 2016-2021 ($ millions)
  • Exhibit 27: Global OAB therapeutics market share by geography 2016-2021 (%)
  • Exhibit 28: Global OAB therapeutics market scenario in different regions
  • Exhibit 29: Market scenario in Americas
  • Exhibit 30: OAB therapeutics market in Americas 2016-2021 ($ millions)
  • Exhibit 31: Prevalence rate of OAB in US 2007
  • Exhibit 32: Market scenario in EMEA
  • Exhibit 33: OAB therapeutics market in EMEA 2016-2021 ($ millions)
  • Exhibit 34: Market scenario in APAC
  • Exhibit 35: OAB therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 36: Probability of continuing antimuscarinic treatment in patients depending on their age
  • Exhibit 37: Geriatric population analysis by geography 2000 and 2030 (estimated) (in millions)
  • Exhibit 38: Prevalence rate of OAB in different age groups in Finland 2003-2004 (%)
  • Exhibit 39: OAB-POLL survey in US adults 2010
  • Exhibit 40: Telephonic interview evaluating the treatment outcomes with antimuscarinic agents in OAB patients
  • Exhibit 41: Competitive structure analysis of global OAB therapeutics market 2016
  • Exhibit 42: Allergan: Key highlights
  • Exhibit 43: Allergan: Strength assessment
  • Exhibit 44: Allergan: Strategy assessment
  • Exhibit 45: Allergan: Opportunity assessment
  • Exhibit 46: Astellas Pharma: Key highlights
  • Exhibit 47: Astellas Pharma: Strength assessment
  • Exhibit 48: Astellas Pharma: Strategy assessment
  • Exhibit 49: Astellas Pharma: Opportunity assessment
  • Exhibit 50: Hisamitsu Pharmaceutical: Key highlights
  • Exhibit 51: Hisamitsu Pharmaceutical: Strength assessment
  • Exhibit 52: Hisamitsu Pharmaceutical: Strategy assessment
  • Exhibit 53: Hisamitsu Pharmaceutical: Opportunity assessment
  • Exhibit 54: Pfizer: Key highlights
  • Exhibit 55: Pfizer: Strength assessment
  • Exhibit 56: Pfizer: Strategy assessment
  • Exhibit 57: Pfizer: Opportunity assessment
Back to Top